Dedicated to
Early Intervention.
And Life.

Transforming the early detection and intervention of oral and oropharyngeal cancer

Learn More

National Oral Cancer Awareness Survey Reveals Shocking Statistics

Knowing Earlier to Give Them a LATER®

Worldwide, there are more than 529,000 cases and nearly 292,000 deaths from oral and oropharyngeal cancer each year. The death rate associated with oral cancer is particularly high due to late-stage diagnosis, but early intervention can more than double a patient’s chance of survival.

Learn More

The Science of Earlier®

Vigilant Biosciences® develops advanced and highly accurate methods to aid in the early detection of oral and oropharyngeal cancer through the detection of CD44 and total protein levels collected in a saline solution.

This proprietary technology serves as the platform for the first and only tests to aid in the diagnosis of oral and oropharyngeal cancer by detecting a tumor-initiating and stem cell-associated biomarker. Vigilant Biosciences has developed products for the early detection of oral and oropharyngeal cancer for both the U.S. and non-U.S. markets. These tests empower healthcare providers to improve lives through earlier intervention.

Non-U.S. Markets

OncAlert® Oral Cancer Tests

The OncAlert Oral Cancer Tests are CE Marked and available in select markets outside the United States.

Learn More
U.S. Market

OraMark™ by OncAlert Labs

The OraMark test is processed at OncAlert Labs, LLC, a CLIA-certified lab and part of the Vigilant Biosciences family of companies.

Learn More

Recent News

View All

Media Coverage

View All

Recent News

View All

Upcoming Events

11.13.17 - 11.16.17

MEDICA 2017

View All
View All